Clinical Trials Logo

Relapsed clinical trials

View clinical trials related to Relapsed.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05673057 Recruiting - Leukemia Clinical Trials

Study of MP0533 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Start date: December 29, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of MP0533 in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)

NCT ID: NCT03881774 Recruiting - B Cell Lymphoma Clinical Trials

Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies

Start date: February 27, 2019
Phase: Phase 1
Study type: Interventional

Evaluation the safety and efficacy of cord blood-derived CAR-T cells in patients with relapsed/refractory B cell leukemia/lymphoma whose disease relapsed after autologous CAR-T cells therapy or who fail to preparation for autologous CAR-T cells

NCT ID: NCT03881761 Recruiting - Refractory Clinical Trials

CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma

Start date: February 1, 2019
Phase: Phase 1
Study type: Interventional

Evaluation the safety and efficacy of CD19/CD20 bispecific CAR-T cells in patients with relapsed/refractory B cell lymphoma

NCT ID: NCT02677064 Recruiting - Acute Leukemia Clinical Trials

Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia

Start date: February 2016
Phase:
Study type: Observational

The investigators are doing this research study to assess the percentage of patients receiving stem cell transplantation for the type of blood cancer you have. They want to know how many patients get a transplant and why some patients do get a transplant while others do not. Also they want to explore why some patients elect not to undergo stem cell transplantation, when it is recommended by their physicians.